INDICATIONS

REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

REBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).

REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

Request a Rep

Sitemap

Homepage

Myelodysplastic syndromes (MDS)

THE NEED FOR REBLOZYL

PATIENT IDENTIFICATION

PATIENT OUTCOMES

DOSING AND ADMINISTRATION

SUPPORT AND RESOURCES

Beta-thalassemia

THE NEED FOR REBLOZYL

PATIENT OUTCOMES

DOSING AND ADMINISTRATION

SUPPORT AND RESOURCES

Sitemap

Homepage

Myelodysplastic syndromes (MDS)

THE NEED FOR REBLOZYL

PATIENT IDENTIFICATION

PATIENT OUTCOMES

DOSING AND ADMINISTRATION

SUPPORT AND RESOURCES

Beta-thalassemia

THE NEED FOR REBLOZYL

PATIENT OUTCOMES

DOSING AND ADMINISTRATION

SUPPORT AND RESOURCES

2007-US-2300019     04/2023